ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer
Videos  >  

Monitoring MRD in Patients with AML

Richard M. Stone, MD
Published Online:10:49 AM, Mon October 30, 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in patients with acute myeloid leukemia (AML).
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.